今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

致远互联携手沈鼓集团 共创数字化人力资源管理新篇章

北京，2024年6月17日 - 近日，领先的人力资源管理解决方案供应商致远互联宣布与沈鼓集团达成战略合作，将为沈鼓集团提供全面的人力资源数字化解决方案，助力沈鼓集团打造高效、智能、敏捷的人力资源管理体系，推动其数字化转型升级迈入新阶段。

沈鼓集团有限公司是中国装备制造业的龙头企业，是中国机械工业百强企业之一，国家特大型一档企业。沈鼓集团始终坚持以科技创新为引领，致力于为客户提供高效、可靠、节能的装备产品和服务。近年来，沈鼓集团积极推进数字化转型，将数字化技术融入企业运营管理全过程，以提升企业竞争力和核心价值创造能力。

致远互联作为国内领先的人力资源管理解决方案供应商，拥有深厚的人力资源管理专业知识和丰富的行业经验，为众多知名企业提供数字化人力资源解决方案，助力企业实现人力资源管理的数字化转型升级。致远互联的人力资源数字化解决方案涵盖了人力资源管理的全业务流程，包括招聘、绩效、薪酬、培训、社保、离职等，能够帮助企业打造高效、智能、敏捷的人力资源管理体系，提升人力资源管理效率和效能。

此次致远互联与沈鼓集团的战略合作，是双方强强联合、优势互补的重大举措。双方将充分发挥各自优势，共同推进沈鼓集团人力资源管理的数字化转型升级。致远互联将为沈鼓集团提供全面的人力资源数字化解决方案，助力沈鼓集团构建以人为本、数据驱动、智能决策的人力资源管理体系，提升人力资源管理水平，为沈鼓集团的高质量发展提供强有力的人才支撑。

致远互联总裁表示：“我们非常高兴与沈鼓集团达成战略合作。沈鼓集团是中国装备制造业的领军企业，我们相信致远互联的人力资源数字化解决方案能够助力沈鼓集团打造世界一流的人力资源管理体系，为沈鼓集团的数字化转型升级提供强有力的支持。”

沈鼓集团人力资源部表示：“致远互联是国内领先的人力资源管理解决方案供应商，拥有丰富的行业经验和领先的技术实力。我们相信与致远互联的合作，将能够帮助我们进一步提升人力资源管理水平，助力沈鼓集团的高质量发展。”

此次致远互联与沈鼓集团的战略合作，是人力资源管理数字化转型升级的典范，将为行业树立标杆，推动行业整体水平的提升。